Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment

被引：32

作者：

Gilliam, Bruce L. ^{[1
]}

Heredia, Alonso ^{[1
]}

DeVico, Anthony ^{[1
]}

Le, Nhut ^{[1
]}

Bamba, Douty ^{[1
]}

Bryant, Joseph L. ^{[1
]}

Pauza, C. David ^{[1
]}

Redfield, Robert R. ^{[1
]}

机构：

[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA

来源：

AIDS | 2007年 / 21卷 / 15期

关键词：

D O I：

10.1097/QAD.0b013e3282f02a4f

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

G1 cytostatic drugs reduce CCR5 co-receptor expression and enhance the antiviral activity of a CCR5 antagonist in vitro. The administration of rapamycin, a G1 cytostatic agent, to three cynomolgous macaques led to decreased CCR5 messenger RNA expression in peripheral blood mononuclear cells and cervicovaginal tissue. These results support further clinical evaluation of G1 cytostatic agents such as rapamycin targeting the downregulation of CCR5 expression as a strategy for both the prevention and treatment of HIV infection.

引用

页码：2108 / 2110

页数：3

共 50 条

[1] CCR5 antagonists in the treatment of treatment-experienced patients infected with CCR5 tropic HIV-1
Lorenzen, Thore
Stoehr, Albrecht
Walther, Irene
Plettenberg, Andreas
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 419 - 425
[2] CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1
Bredeek, U. Fritz
Harbour, Michael J.
EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2007, 12 (09) : 427 - 434
[3] Maraviroc - a CCR5 antagonist for the treatment of HIV-1 infection
Van Der Ryst, Elna
FRONTIERS IN IMMUNOLOGY, 2015, 6
[4] CCR5 HIV-1 vertical transmission
Shearer, WT
Kalish, LA
Zimmerman, PA
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (02): : 180 - 181
[5] CCR5 inhibitors in HIV-1 therapy
Dorr, Patrick
Perros, Manos
EXPERT OPINION ON DRUG DISCOVERY, 2008, 3 (11) : 1345 - 1361
[6] The reduction in density of CCR5 coreceptors by rapamycin improves Vicriviroc antiviral activity on HIV-1
Boulestin, A.
VIROLOGIE, 2009, 13 (02) : 118 - 118
[7] Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients
Soulie, Cathia
Malet, Isabelle
Lambert-Niclot, Sidonie
Tubiana, Roland
Thevenin, Monique
Simon, Anne
Murphy, Robert
Katlama, Christine
Calvez, Vincent
Marcelin, Anne-Genevieve
AIDS, 2008, 22 (16) : 2212 - 2214
[8] Choosing CCR5 or Rev siRNA in HIV-1
Arteaga, HJ
Hinkula, J
van Dijk-Härd, I
Dilber, MS
Wahren, B
Christensson, B
Mohamed, AJ
Smith, CIE
NATURE BIOTECHNOLOGY, 2003, 21 (03) : 230 - 231
[9] CCR5 monoclonal antibodies for HIV-1 therapy
Olson, William C.
Jacobson, Jeffrey M.
CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 104 - 111
[10] HIV-1 infection and CCR5Δ32 homozygosis
Ballana, Ester
Este, Jose A.
FUTURE VIROLOGY, 2012, 7 (07) : 653 - 658

← 1 2 3 4 5 →